Hanseatic Management Services Inc Neurocrine Biosciences Inc Transaction History

Hanseatic Management Services Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	BUY	$106.72 - $127.06 $486,536 - $579,266	4,559 New	4,559 $545,000
Q1 2020 Apr 22, 2020	SELL	$75.11 - $113.76 $679,520 - $1.03 Million	-9,047 Closed	0 $0
Q4 2019 Jan 29, 2020	BUY	$86.8 - $118.57 $785,279 - $1.07 Million	9,047 New	9,047 $972,000
Q4 2018 Jan 29, 2019	SELL	$68.32 - $124.36 $717,838 - $1.31 Million	-10,507 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $238,004 - $302,920	-2,407 Reduced 18.64%	10,507 $1.29 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $34,788 - $48,967	462 Added 3.71%	12,914 $1.27 Million
Q1 2018 May 02, 2018	BUY	$75.88 - $92.43 $1,593 - $1,941	21 Added 0.17%	12,452 $1.03 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $727,586 - $964,521	12,431	12,431 $965,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Hanseatic Management Services Inc, based on Form 13F filings with the SEC.

Stay updated on Hanseatic Management Services Inc with notifications on news.